Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats

Teratology

Volumn 60, Issue 2, 1999, Pages 68-73

  Patlas, N ^a   Golomb, G ^b   Yaffe, P ^a   Pinto, T ^b   Breuer, E ^b   Ornoy, A ^a  

^a HEBREW UNIVERSITY   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; UNCLASSIFIED DRUG; VS B6;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; BONE MALFORMATION; BONE MARROW; CALCIUM BONE LEVEL; CARTILAGE; CHEMICAL ANALYSIS; CHEMICAL TERATOGENESIS; CONTROLLED STUDY; FEMALE; FETUS; FETUS DEVELOPMENT; HISTOLOGY; ISOTOPE LABELING; MESENCHYME; MINERALIZATION; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; PLACENTAL TRANSFER; PRENATAL EXPOSURE; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; TERATOGENICITY; TRABECULAR BONE;

ALENDRONATE; ANIMALS; BONE AND BONES; CALCIFICATION, PHYSIOLOGIC; DIPHOSPHONATES; FEMALE; FETUS; PREGNANCY; RATS; RATS, WISTAR;

ANIMALIA;

EID: 0032766937     PISSN: 00403709     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9926(199908)60:2<68::AID-TERA10>3.0.CO;2-H     Document Type: Article

References (25)

1. Cohen, H, Solomon V, Alferiev I, Breuer E, Ornoy A, Patlas N, Eidelman N, Hagele G, Golomb G. 1998. Bisphosphonates and tetracycline: experimental models for their evaluation in calcium-related disorders. Pharm Res 15:604-611.
2. Flanagan, AM, Chambers TJ. 1991. Inhibition of bone resorption by bisphosphonates: interaction between bisphosphonates, osteoclasts, and bone. Calcif Tissue Int 49:407-415.
3. Fleisch H. 1987. Bisphosphonates - history and experimental basis. Bone [Suppl] 8:23-28.
4. Fleisch H. 1997a. Bisphosphonates: preclinical aspects and use in osteoporosis. Ann Med 29:55-62.
5. Fleisch H. 1997b. Bisphosphonates in bone disease: from the laboratory to the patient, 3rd ed. New York, London: Parthenon Publishing Groups, p 184.
6. Geddes AD, D'Souza SM, Ebetino FH, Ibbotson KJ. 1994. Bisphosphonates: structure-activity relationships and therapeutic implications. Bone Miner Res 8:265-306.
7. Hosking DJ. 1990. Advances in the management of Paget's disease of bone. Drugs 40:829-840.
8. Liberman U, Weiss S, Broll J, Minne H, Quan H, Bell N, Rodriguez-Portales J, Downs R, Dequeker J, Favus M, Seemen E, Recker R, Capizzi T, Santora A, Lombardi A, Shah R, Hirsch L, Karpf D. 1995. Effect of oral alendronate on bone mineral density and incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437-1443.
9. 2 on fetal osteogenesis and ossification in rats. Teratology 4:383-394.
10. Ornoy A. 1973. Transplancental effect of estrogen on osteogenesis in rat fetuses. Pathology 5:183-188.
11. Ornoy A. 1995. Comparative aspects of cartilage and bone formation in man, rats and mice. In: Ornoy A, editor. Animal models of human related calcium metabolic disorders. Boca Raton, FL: CRC Press, p 1-22.
12. Ornoy A, Horowitz A. 1972. Postnatal effects of maternal hypercortisonism on skeletal development in newborn rats. Teratology 6:153-158.
13. 2. Arch Pathol 87:563-571.
14. 2. Isr J Med Sci 8:943-949.
15. Papapoulos SE, Landman JO, Bijvoet OLM, Lowik CWGM, Valkema R, Pauwels EKJ, Vermeij P. 1992. The use of bisphosphonates in the treatment of osteoporosis. Bone [Suppl] 13:S91-S93.
16. Peshin J, Ornoy A, Menczel J. 1976. Transplacental effect of thyrocalcitonin on intestinal calcium-binding protein, alkaline phosphatase activity and ossification of long bones in rat fetuses. Isr J Med Sci 12:248-256.
17. Plosker GL, Goa KL. 1994. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 47:945-dash;982.
18. Rodan GA, Balena R. 1993. Bisphosphonates in the treatment of metobolic bone diseases. Ann Med 25:373-378.
19. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA. 1991. Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88:2095-2105.
20. Schwartz Z, Soskolne W, Neubauer T, Goldstein M, Adi S, Ornoy A. 1991. Direct and sex specific enhancement of bone formation and calcification by sex steroids in vitro (biochemical and morphometric study). Endocrinology 129:1164-1173.
21. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OHN. 1990. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265-1271.
22. Van Gelder JM, Golomb G. 1995. The evaluation of bisphosphonates as potential drugs for the treatment of calcium-related disorders. In: Ornoy A, editor. Animal models of human related calcium metabolic disorders. Boca Raton: CRC Press, p 181-205.
23. Watts N, Harris S, Genant H, Wasnich R, Miller P, Jackson R, Licata A, Ross P, Woodson G, Yanover M, Mysiw W, Kohse L, Rao M, Steiger P, Richmond B, Chesnut CH III. 1990. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73-79.
24. Wronski TJ, Dann LM, Qi H, Yen C-F. 1993. Skeletal effects of withdrawal of estrogen and diphosphonate treatment in ovariectomized rats. Calfif Tissue Int 53:210-216.
25. 3 on the limb skeleton of fetuses and offspring in rats. Acta Anat (Basel) 111:343-351.